| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | — | — | — | — | — | — | 1.45 | 0.32 | 2.78 | 2.60 | 3.59 | 6.54 |
| Quick Ratio | — | — | — | — | — | — | 1.45 | 0.32 | 2.78 | 2.60 | 3.55 | 6.24 |
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.00 | 0.54 | 0.02 | 0.00 | -0.86 | — | — | — | — |
| ROE | -45.90% | -56.58% | -44.58% | -27.47% | -80.09% | -276.08% | -1737.79% | 753.94% | -237.77% | -170.25% | -125.50% | -151.88% |
| ROA | -42.40% | -51.57% | -41.86% | -26.94% | -49.06% | -185.44% | -248.50% | -1193.10% | -190.77% | -136.98% | -100.88% | -131.41% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Book Value / Share | 2.13 | 2.35 | 2.27 | 8.21 | 3.40 | 1.28 | — | — | — | — | — | 0.68 |
Rezolute, Inc. is a late-stage rare disease company focused on developing therapies to improve outcomes for individuals with hypoglycemia caused by hyperinsulinism, including congenital and tumor forms. Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds to an allosteric site on the insulin receptor in target tissues like the liver, fat, and muscle. Ersodetug is in Phase 3 clinical trials for congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive insulin production, and for tumor hyperinsulinism. The company is also advancing RZ402, an oral plasma kallikrein inhibitor designed for the chronic treatment of diabetic macular edema, a diabetes-related vascular complication leading to vision impairment by blocking bradykinin production to reduce vascular leakage and inflammation. Rezolute, Inc. operates in the biotechnology sector, targeting unmet needs in rare metabolic and ophthalmologic disorders. Founded in 2010 and headquartered in Redwood City, California, it emphasizes innovative antibody and small molecule therapies for severe, life-threatening conditions.